The milestone is a modest validation of the Exelixis partnership but does not change the company's fundamental outlook. Traders should watch for clinical data from the lead program muzastotug (ADG126) in MSS CRC, as that remains the primary value driver. The $2M payment provides a small cash buffer but is not material.
Price Chart
Executive Summary
Adagene announced a $2.0M milestone payment from Exelixis for a preclinical milestone on XB404, a SAFEbody ADC candidate targeting ROR1/2-expressing tumors. An additional payment was triggered by candidate selection for another ADC program. While the milestone validates the collaboration, the $2M payment is modest relative to Adagene's $231M market cap and represents only preclinical progress, limiting near-term stock impact.
Key Facts
- Achieved preclinical milestone for XB404, triggering a $2.0M payment from Exelixis.
- Additional payment from Exelixis triggered by candidate selection for another SAFEbody ADC program.
- Adagene eligible for future development/commercialization milestones and royalties on net sales.
- XB404 is designed to deliver cytotoxic payload to ROR1/2-expressing tumors using Adagene's SAFEbody masking technology.
- Exelixis has the right to use SAFEbody platform to generate masked monoclonal antibodies for ADC development.
Financial Impact
$2.0M milestone payment received; additional payment undisclosed amount. Total near-term value limited relative to $231M market cap.
Risk Factors
- Preclinical milestone does not guarantee clinical success or future milestone payments.
- Dependence on partnership with Exelixis; any termination or delay could impact pipeline progress.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-106137 |
| Document: tm2624926d1_ex99-1.htm | 0001104659-26-106137 |
| Document: 0001104659-26-106137-index-headers.html | 0001104659-26-106137 |
| Document: 0001104659-26-106137-index.html | 0001104659-26-106137 |
| Document: 0001104659-26-106137.txt | 0001104659-26-106137 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $3.20 | awaiting T+60 | — | $2.44 (−23.59%) |
Sep 22, 2026 4w ago | 6-K | $3.23 | awaiting T+60 | — | $2.44 (−24.30%) |
Sep 10, 2026 6w ago | 6-K | $3.31 | awaiting T+60 | — | $2.44 (−26.13%) |
Sep 9, 2026 6w ago | 6-K | $3.27 | awaiting T+60 | — | $2.44 (−25.23%) |
Aug 16, 2026 10w ago | Institutional Cluster | $3.83 | awaiting T+60 | — | $2.44 (−36.16%) |
Aug 12, 2026 10w ago | 6-K | $3.75 | awaiting T+60 | — | $2.44 (−34.80%) |
Aug 12, 2026 10w ago | Press Release | $3.75 | awaiting T+60 | — | $2.44 (−34.80%) |
Jul 6, 2026 16w ago | 6-K | $3.93 $3.21 | ▼ −18.32% | ▼ −20.04% | $2.44 (−37.79%) |
Apr 17, 2026 27w ago | 6-K | $3.89 $3.67 | ▼ −5.66% | ▼ −12.43% | $2.44 (−37.15%) |
Apr 2, 2026 29w ago | 6-K | $3.99 $4.20 | ▼ −5.26% | ▲ +8.90% | $2.44 (+38.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers